Discriminating the contribution of unmodifiable random intrinsic DNA replication errors ('bad
luck') to cancer development from those of other factors is critical for understanding cancer in …

Molecularly targeted cancer therapies substantially improve patient outcomes, although the
durability of their effectiveness can be limited. Resistance to these therapies is often related …

Fusion oncoproteins (FOs) arise from chromosomal translocations in~ 17% of cancers and
are often oncogenic drivers. Although some FOs can promote oncogenesis by undergoing …

Gene fusions represent an important class of somatic alterations in cancer. We
systematically investigated fusions in 9,624 tumors across 33 cancer types using multiple …

Defining direct targets of transcription factors and regulatory pathways is key to
understanding their roles in physiology and disease. We combined SLAM-seq [thiol (SH) …

We established a genome-wide compendium of somatic mutation events in 3949 whole
cancer genomes representing 19 tumor types. Protein-coding events captured well …

Protein kinases play a major role in cellular activation processes, including signal
transduction by diverse immunoreceptors. Given their roles in cell growth and death and in …

Protease-targeted chimeras (PROTACs) are a new technology that is receiving much
attention in the treatment of diseases. The mechanism is to inhibit protein function by …

Although the use of ATP-competitive tyrosine kinase inhibitors of oncoprotein BCR-ABL1
has enabled durable responses in patients with chronic myeloid leukemia (CML), issues of …

The Abelson (ABL) family of nonreceptor tyrosine kinases, ABL1 and ABL2, transduces
diverse extracellular signals to protein networks that control proliferation, survival, migration …